Narrative updates are currently in beta.

Back to narrative

Clinical Pipeline And AI Integration Will Advance Antibody Therapies

ABCL logo
ABCL
AnalystConsensusTarget
Not Invested
Published 18 May 2025

Update shared on29 Jul 2025

Fair value Increased 10%
AnalystConsensusTarget's Fair Value
US$9.29
51.5% undervalued intrinsic discount
14 Aug
US$4.50
Loading
1Y
71.8%
7D
6.1%

The increased consensus price target for AbCellera Biologics is primarily supported by a higher future P/E ratio—implying stronger growth expectations—resulting in an upward revision from $8.43 to $9.14.


What's in the News


  • AbCellera received a No Objection Letter from Health Canada for its Clinical Trial Application for ABCL575, an antibody targeting OX40L for atopic dermatitis and other inflammatory conditions; Phase 1 study to begin in Q3 2025.
  • The company was issued a No Objection Letter from Health Canada for its Clinical Trial Application for ABCL635, a first-in-class antibody targeting NK3R for non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause; Phase 1 trial to begin in Q3 2025.
  • The U.S. Court of Appeals for the Federal Circuit affirmed the validity of AbCellera’s U.S. Patent No. 10,087,408 related to microfluidic devices, strengthening its position in ongoing litigation with Bruker Corporation.

Valuation Changes


Summary of Valuation Changes for AbCellera Biologics

  • The Consensus Analyst Price Target has risen from $8.43 to $9.14.
  • The Future P/E for AbCellera Biologics has risen from 244.50x to 262.99x.
  • The Net Profit Margin for AbCellera Biologics remained effectively unchanged, moving only marginally from 13.79% to 13.91%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.